TB-500 vs Apraglutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
TB-500 is a synthetic peptide that copies the active region of thymosin beta-4, a natural protein that controls how cells build and move their internal skeleton. Most TB-500 products reproduce the short LKKTETQ sequence (residues 17 to 23) responsible for binding actin and driving cell migration, which is why it gets marketed for tendon, muscle, and wound repair. Here is the honest part: there are essentially no completed human trials of the TB-500 fragment itself, and almost all the human clinical data is for the full-length thymosin beta-4 molecule, which is related but not the same thing.
Also: FE 203799, Once-weekly GLP-2 analog
Apraglutide is a once-weekly GLP-2 analog for short bowel syndrome, originally from VectivBio and now owned by Ironwood Pharmaceuticals. Its phase 3 STARS trial hit its main goal in 2024, but in April 2025 Ironwood said the FDA wanted a confirmatory trial, partly because patients in STARS got less drug exposure than planned due to how doses were prepared and given. That new trial, STARS-2, started in June 2026, so approval is years away (a submission before end of 2029 has been mentioned).
Key Comparison Insights
- Both peptides belong to the Healing category, suggesting similar primary applications.
- Apraglutide has stronger research evidence (Human Trials) compared to TB-500 (Animal Studies).
Detailed Comparison
| Attribute | TB-500 | Apraglutide |
|---|---|---|
| Category | Healing | Healing |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Thymosin beta-4 works by grabbing onto G-actin, the building-block form of actin, and acting as the main reservoir cells use to remodel their cytoskeleton. That control over actin lets cells migrate into wounds, which is the proposed basis for faster tissue repair. The active heptapeptide sequence LKKTETQ is the piece that does the actin binding, and TB-500 is built around it. Beyond cell movement, thymosin beta-4 has shown anti-inflammatory effects and pro-angiogenic activity in lab models. Keep in mind that injecting a short synthetic fragment is not guaranteed to reproduce everything the full protein does, so the mechanism story is borrowed largely from research on the parent molecule. | Like teduglutide and glepaglutide, apraglutide activates GLP-2 receptors in the gut, signaling the intestinal lining to grow and absorb more. It was engineered for very low clearance and high plasma protein binding, which gives it a much longer half-life. In rat studies its IV half-life was about 159 minutes versus 19 for teduglutide and 16 for glepaglutide, and it kept more gut-growth activity when dosed less often. That is the basis for once-weekly dosing in humans. Same class caveat as the others: long-term stimulation of gut tissue growth carries a theoretical polyp and tumor risk that requires monitoring. |
| Common Dosing | 2-2.5 mg twice weekly (loading), then 2.5 mg once weekly (maintenance) 2x weekly for 4-6 weeks, then 1x weekly | 2.5-5 mg once weekly by body weight (trial dose) Once weekly |
| Administration | Subcutaneous or intramuscular injection | Subcutaneous injection once weekly |
| Typical Duration | 4-6 weeks loading, then maintenance | 24-week primary endpoint, with treatment continued to week 48 and beyond in STARS |
| Best Time to Take | Morning or evening | Same day each week (trial schedule) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The strongest evidence is preclinical and is mostly about full-length thymosin beta-4, not the TB-500 fragment. Animal studies consistently show accelerated wound healing, reduced scarring, and improved recovery in tendon, skin, and cardiac injury models. On the human side, the biotech company RegeneRx ran the molecule (as RGN-259 eye drops and RGN-352 injection) through actual clinical trials: a placebo-controlled Phase 3 study of RGN-259 in neurotrophic keratopathy reported corneal healing in 6 of 10 treated patients versus 1 of 8 on placebo, and an injectable cardiac program reached Phase 2 before a manufacturing hold. But those programs used full-length thymosin beta-4, not the 7-amino-acid TB-500 fragment sold for research. For the fragment specifically, there are no completed, published human efficacy trials for muscle or tendon repair, and a recently listed cardiovascular biomarker study is early-stage. So: real animal data, real human data for the parent protein, and a near-total gap for TB-500 as sold. | STARS (NCT04627025) randomized 164 adults with SBS and intestinal failure 2:1 to weekly apraglutide (2.5 mg or 5 mg by body weight) or placebo. Topline results in February 2024: weekly parenteral support volume fell 25.5% versus 12.5% on placebo at week 24 (p=0.001). In stoma patients the gap was bigger (25.6% vs 7.8%), and 43% vs 27.5% gained at least one day a week off IV support. But the colon-in-continuity endpoints missed, and enteral autonomy at week 48 (12.5% vs 7.4%) was not significant. Discontinuation for side effects was low (3.6% vs 1.9%). While preparing the NDA, Ironwood found exposure in STARS was lower than intended because of dose preparation and administration, and in April 2025 said the FDA required a confirmatory trial. STARS-2 is a 24-week, placebo-controlled trial of about 124 patients (NCT07742735), started June 2026. So: a positive phase 3 on paper, with a dosing problem that undercuts confidence, and no approval in sight before the end of the decade. |
Frequently Asked Questions: TB-500 vs Apraglutide
What is the difference between TB-500 and Apraglutide?
TB-500 is a healing peptide that tb-500 is a synthetic peptide that copies the active region of thymosin beta-4, a natural protein that controls how cells build and move their internal skeleton. most tb-500 products reproduce the short lkktetq sequence (residues 17 to 23) responsible for binding actin and driving cell migration, which is why it gets marketed for tendon, muscle, and wound repair. here is the honest part: there are essentially no completed human trials of the tb-500 fragment itself, and almost all the human clinical data is for the full-length thymosin beta-4 molecule, which is related but not the same thing. Apraglutide is a healing peptide that apraglutide is a once-weekly glp-2 analog for short bowel syndrome, originally from vectivbio and now owned by ironwood pharmaceuticals. its phase 3 stars trial hit its main goal in 2024, but in april 2025 ironwood said the fda wanted a confirmatory trial, partly because patients in stars got less drug exposure than planned due to how doses were prepared and given. that new trial, stars-2, started in june 2026, so approval is years away (a submission before end of 2029 has been mentioned). The main differences lie in their mechanisms of action and clinical applications.
Which is better, TB-500 or Apraglutide?
Neither is universally "better" - the choice depends on your specific goals. TB-500 is typically used for healing purposes, while Apraglutide is used for healing. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can TB-500 and Apraglutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using TB-500 and Apraglutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.